Boston Scientific Receives FDA Approval for Pivotal ATLAS Clinical Trial of Next-Generation TAXUS Liberte Coronary Stent System

Strategic Insights -

Boston Scientific Corp. has announced that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to conduct its ATLAS clinical trial, assessing the safety and efficacy of the company's next-generation TAXUS Liberte coronary stent system. The Liberte stent, designed to enhance deliverability and conformability, particularly in challenging lesions, will be the basis for the trial. This pivotal study aims to collect data to support regulatory filings for product commercialization and is expected to enroll 822 patients across multiple international sites.

Key Takeaways:

  • The ATLAS clinical trial is a pivotal study designed to assess the safety and efficacy of the TAXUS Liberte stent system for the treatment of coronary artery disease.
  • The trial will enroll 822 patients across 60 sites in the United States, Canada, Australia, New Zealand, Singapore, Hong Kong, and Taiwan.
  • The TAXUS Liberte stent is designed to enhance deliverability and conformability, particularly in challenging lesions, and is built upon Boston Scientific's existing bare metal version of the Liberte stent.
  • The study aims to support regulatory filings for product commercialization, indicating a significant step in the approval process for the TAXUS Liberte stent system.
  • Keith Dawkins, a consultant cardiologist, has expressed interest in the stent, highlighting its excellent conformability and deliverability in challenging lesions.
  • Angiotech Pharmaceuticals, Inc., a corporate partner of Boston Scientific, is a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials.

Statistics:

  • 822 patients will be enrolled in the ATLAS clinical trial.
  • 60 international sites will participate in the trial.
  • The trial will assess the safety and efficacy of the TAXUS Liberte stent system for the treatment of coronary artery disease.
  • The ATLAS trial is expected to collect data to support regulatory filings for product commercialization.

Sources:

  • Boston Scientific Corp.
  • U.S. Food and Drug Administration (FDA)
  • Angiotech Pharmaceuticals, Inc.
  • Keith Dawkins, consultant cardiologist, Wessex Cardiothoracic Centre, Southampton University Hospital, Southampton, England.